Biotechnology company developing precision therapies for genetically defined diseases.
Cogent Biosciences, Inc. is a pioneering biotechnology firm dedicated to advancing precision therapies tailored for genetically defined diseases. At the forefront of its innovative pipeline is CGT9486, a selective tyrosine kinase inhibitor meticulously crafted to target the KIT D816V mutation responsible for driving systemic mastocytosis. This promising candidate also addresses other mutations within KIT exon 17, notably those prevalent in advanced gastrointestinal stromal tumors.
In collaboration with Plexxikon Inc., Cogent Biosciences has forged a strategic licensing agreement aimed at accelerating the research, development, and commercialization of bezuclastinib. This partnership underscores the company's commitment to leveraging cutting-edge scientific insights to tackle complex medical challenges and bring transformative therapies to patients in need.
Founded in 2014 and headquartered in Cambridge, Massachusetts, Cogent Biosciences, Inc. was initially known as Unum Therapeutics Inc. before rebranding in October 2020. The company's evolution reflects its steadfast dedication to pioneering scientific excellence and innovation in the biopharmaceutical industry, with a strategic focus on delivering breakthrough therapies that address the underlying genetic drivers of disease.